PMID- 34517295
OWN - NLM
STAT- MEDLINE
DCOM- 20211216
LR  - 20221221
IS  - 1096-0961 (Electronic)
IS  - 1079-9796 (Print)
IS  - 1079-9796 (Linking)
VI  - 92
DP  - 2021 Dec
TI  - COVID-19 induces proatherogenic alterations in moderate to severe non-comorbid 
      patients: A single-center observational study.
PG  - 102604
LID - S1079-9796(21)00070-X [pii]
LID - 10.1016/j.bcmd.2021.102604 [doi]
AB  - Patients with COVID-19 can be asymptomatic or present mild to severe symptoms, 
      leading to respiratory and cardiovascular complications and death. Type 2 
      diabetes mellitus (T2DM) and obesity are considered risk factors for COVID-19 
      poor prognosis. In parallel, COVID-19 severe patients exhibit dyslipidemia and 
      alterations in neutrophil to lymphocyte ratio (NLR) associated with disease 
      severity and mortality. To investigate whether such alterations are caused by the 
      infection or results from preexisting comorbidities, this work analyzed 
      dyslipidemia and the hemogram profile of COVID-19 patients according to the 
      severity and compared with patients without T2DM or obesity comorbidities. 
      Dyslipidemia, with a marked decrease in HDL levels, and increased NLR accompanied 
      the disease severity, even in non-T2DM and non-obese patients, indicating that 
      COVID-19 causes the observed alterations. Because decreased hemoglobin is 
      involved in COVID-19 severity, and hemoglobin concentration is associated with 
      metabolic diseases, the erythrogram of patients was also evaluated. We verified a 
      drop in hemoglobin and erythrocyte number in severe patients, independently of 
      T2DM and obesity, which may explain in part the need for artificial ventilation 
      in severe cases. Thus, the control of such parameters (especially HDL levels, 
      NLR, and hemoglobin concentration) could be a good strategy to prevent COVID-19 
      complications and death.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Kimura, Louise F
AU  - Kimura LF
AD  - Laboratory of Pain and Signaling, Butantan Institute, Avenida Vital Brazil 1500, 
      Sao Paulo, SP 05503-900, Brazil. Electronic address: 
      louise.vieira@esib.butantan.gov.br.
FAU - Sant'Anna, Morena B
AU  - Sant'Anna MB
AD  - Laboratory of Pain and Signaling, Butantan Institute, Avenida Vital Brazil 1500, 
      Sao Paulo, SP 05503-900, Brazil. Electronic address: 
      morena.santanna@esib.butantan.gov.br.
FAU - Andrade, Sonia A
AU  - Andrade SA
AD  - Laboratory of Pain and Signaling, Butantan Institute, Avenida Vital Brazil 1500, 
      Sao Paulo, SP 05503-900, Brazil. Electronic address: 
      sonia.andrade@butantan.gov.br.
FAU - Ebram, Matteo C
AU  - Ebram MC
AD  - Laboratory of Pain and Signaling, Butantan Institute, Avenida Vital Brazil 1500, 
      Sao Paulo, SP 05503-900, Brazil. Electronic address: matteo.celano@fm.usp.br.
FAU - Lima, Cristiane F G
AU  - Lima CFG
AD  - Laboratory of Pain and Signaling, Butantan Institute, Avenida Vital Brazil 1500, 
      Sao Paulo, SP 05503-900, Brazil. Electronic address: 
      cristiane.lima@esib.butantan.gov.br.
FAU - Celano, Rosa M G
AU  - Celano RMG
AD  - University of Taubate (UNITAU), Rua Quatro de Marco, 432, Taubate, SP 12020-270, 
      Brazil. Electronic address: ebramcelano@uol.com.br.
FAU - Viegas, Ruy F M
AU  - Viegas RFM
AD  - University of Taubate (UNITAU), Rua Quatro de Marco, 432, Taubate, SP 12020-270, 
      Brazil. Electronic address: ruyfelipe@endocard.com.br.
FAU - Picolo, Gisele
AU  - Picolo G
AD  - Laboratory of Pain and Signaling, Butantan Institute, Avenida Vital Brazil 1500, 
      Sao Paulo, SP 05503-900, Brazil. Electronic address: 
      gisele.picolo@butantan.gov.br.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20210909
PL  - United States
TA  - Blood Cells Mol Dis
JT  - Blood cells, molecules & diseases
JID - 9509932
RN  - 0 (Hemoglobins)
RN  - 0 (Lipoproteins, HDL)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anemia/epidemiology/etiology
MH  - Atherosclerosis/epidemiology/*etiology
MH  - COVID-19/blood/*complications/therapy
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/epidemiology
MH  - Dyslipidemias/epidemiology/*etiology
MH  - Erythrocyte Count
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Hypoxia/etiology/therapy
MH  - *Leukocyte Count
MH  - Lipoproteins, HDL/blood
MH  - Lymphocyte Count
MH  - Middle Aged
MH  - Neutrophils
MH  - Obesity/epidemiology
MH  - Respiration, Artificial
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *SARS-CoV-2
MH  - Severity of Illness Index
PMC - PMC8426321
OTO - NOTNLM
OT  - COVID-19
OT  - Dyslipidemia
OT  - Hemoglobin concentration
OT  - Neutrophil to lymphocyte ratio
OT  - SARS-CoV-2
COIS- Authors declare no conflict of interest.
EDAT- 2021/09/14 06:00
MHDA- 2021/12/17 06:00
PMCR- 2021/09/09
CRDT- 2021/09/13 20:38
PHST- 2021/06/21 00:00 [received]
PHST- 2021/08/25 00:00 [revised]
PHST- 2021/08/26 00:00 [accepted]
PHST- 2021/09/14 06:00 [pubmed]
PHST- 2021/12/17 06:00 [medline]
PHST- 2021/09/13 20:38 [entrez]
PHST- 2021/09/09 00:00 [pmc-release]
AID - S1079-9796(21)00070-X [pii]
AID - 102604 [pii]
AID - 10.1016/j.bcmd.2021.102604 [doi]
PST - ppublish
SO  - Blood Cells Mol Dis. 2021 Dec;92:102604. doi: 10.1016/j.bcmd.2021.102604. Epub 
      2021 Sep 9.